Furthermore, the integration of CD47 blockade, MET inhibitors, and anti-CTLA-4 therapy engages both the innate and adaptive immune systems, enhancing phagocytosis, reducing tumor growth, and strengthening immune responses. The gene discussed is CTLA4; the disease is neoplasm.